Sumitomo Mitsui Trust Group Inc. Sells 15,281 Shares of DaVita Inc. $DVA

Sumitomo Mitsui Trust Group Inc. reduced its stake in DaVita Inc. (NYSE:DVA) by 13.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 98,222 shares of the company’s stock after selling 15,281 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in DaVita were worth $13,051,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Hantz Financial Services Inc. grew its holdings in shares of DaVita by 48.1% in the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in DaVita in the 2nd quarter valued at $36,000. Canada Pension Plan Investment Board bought a new stake in shares of DaVita during the second quarter worth $43,000. Ameritas Advisory Services LLC bought a new position in shares of DaVita in the second quarter worth about $47,000. Finally, Employees Retirement System of Texas acquired a new stake in shares of DaVita in the second quarter valued at approximately $49,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Stock Down 1.0%

DVA opened at $104.76 on Friday. The stock has a market cap of $7.40 billion, a P/E ratio of 10.79, a P/E/G ratio of 0.64 and a beta of 0.99. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $179.60. The company has a fifty day simple moving average of $116.14 and a 200 day simple moving average of $127.70.

DaVita (NYSE:DVA) last posted its earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. During the same quarter in the prior year, the firm posted $2.59 earnings per share. The business’s revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DVA has been the subject of a number of research reports. Truist Financial lowered their price objective on DaVita from $140.00 to $128.00 and set a “hold” rating for the company in a research report on Monday, January 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Zacks Research raised shares of DaVita from a “strong sell” rating to a “hold” rating in a research note on Friday, November 28th. TD Cowen reduced their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a research note on Monday, November 3rd. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $145.60.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.